Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic area for MM. At the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France, Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses up-to-date clinical evidence for monoclonal antibody therapies, as well as the potential of bispecific antibodies and antibody-drug conjugates in MM.
Monoclonal antibodies: current and future potential
